NCT03136809View on ClinicalTrials.gov

ALS Treatment Extension Study

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 18, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Cu(II)ATSM

copper-containing synthetic small molecule

Trial Locations (1)

2109

Macquarie University, Sydney

Sponsors
All Listed Sponsors
lead

Collaborative Medicinal Development Pty Limited

INDUSTRY

NCT03136809 - ALS Treatment Extension Study | Biotech Hunter | Biotech Hunter